CompletedNot Applicable

Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination

Germany82 participantsStarted 2022-03-15

Plain-language summary

Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Minimum age of 18 years * Confirmed antiphospholipid syndrome with thromboembolic clinical manifestations (venous thromboembolism, pulmonary embolism, thrombophlebitis etc.) * Patients with APS antibody risk profile (single/double/triple positivity) * Written consent for participation in the prospective APSantiCo observational study Exclusion Criteria: * APS with isolated pregnancy complications * No anticoagulation medication * Inadequately diagnosed APS * Non-compliance on the part of the patient

What they're measuring

change in APS antibody status after surviving COVID-19 infection and/or receiving COVID-19 vaccination

Timeframe: 2015-2022

Trial details

NCT IDNCT05313048

SponsorCardioangiologisches Centrum Bethanien

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-24

View on ClinicalTrials.gov More Antiphospholipid Syndrome trials